Early cancer detection

TumorScan offers a straightforward answer to the current specialist or practitioner’s pain-point.



Disruptive test

Designed as a trigger test for patient at risk of cancer under regular follow-up. 

A comprehensive solution that assists the conventional screening method specialists in their practice and diagnosis.

Patient benefits

Non invasive, better acceptability for regular check up and improve the curative success rate.

Comprehensive offer

Low cost per test includes devices, scanning and analysis system.

Fully automated

High throughput: hundred  tests per platform per day. Limited technical personnel. 

More Informations

Scientific Publications

  • Anderson D., Najafzadeh M., Scally A., Jacob B., Griffith J., Chaha R., Linforth R., Soussaline M., Soussaline F. (2019) Using a Modified Lymphocyte Genome Sensitivity (LGS) test or TumorScan test to detect cancer at an early stage in each individual. FASEB BioAdvances 2019;1:32-39. Read more
  • Kumar Sharma A., Soussaline F., Sallette J. Dybdahl M. (2012) The influence of the number of cells scored on the sensitivity in the comet assay. Mutation Research: Genetic Toxicology and Environmental Mutagenesis 749 (2012) 70-75. Read more
  • Azqueta A., Meier S., Priestley C., Bjerve Gutzkow K., Brunborg G., Sallette J., Soussaline F., Collins A. (2011) The influence of scoring method on variability in results obtained with the comet assay. Mutagenesis, vol. 26 (3) pp. 393-399. Read more